PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia

被引：2
|
作者：
Reeskamp, Laurens F. [1 ]
Tromp, Tycho R. [1 ]
Hovingh, G. Kees [1 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 03期
关键词：
CALCIFICATION; STATINS; EVENTS; RISK;
D O I：
10.1177/2047487319886140
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [41] Targeting PCSK9 for the treatment of hypercholesterolemia
    Hedrick, Joseph A.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (09) : 938 - 946
  • [42] PCSK9 inhibitors for treating hypercholesterolemia
    Pasta, Andrea
    Cremonini, Anna Laura
    Pisciotta, Livia
    Buscaglia, Angelo
    Porto, Italo
    Barra, Fabio
    Ferrero, Simone
    Brunelli, Claudio
    Rosa, Gian Marco
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (03) : 353 - 363
  • [43] PCSK9 Antibodies for the Treatment of Hypercholesterolemia
    Gouni-Berthold, Ioanna
    Berthold, Heiner K.
    NUTRIENTS, 2014, 6 (12): : 5517 - 5533
  • [44] PCSK9 inhibitor therapy and guideline treatment targets for cardiovascular disease and familial hypercholesterolaemia
    Suresh, A.
    Theodoraki, A.
    Ward, E.
    Feher, M. D.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2945 - 2945
  • [45] Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
    Cunningham, David
    Danley, Dennis E.
    Geoghegan, Kieran F.
    Griffor, Matthew C.
    Hawkins, Julie L.
    Subashi, Timothy A.
    Varghese, Alison H.
    Ammirati, Mark J.
    Culp, Jeffrey S.
    Hoth, Lise R.
    Mansour, Mahmoud N.
    McGrath, Katherine M.
    Seddon, Andrew P.
    Shenolikar, Shirish
    Stutzman-Engwall, Kim J.
    Warren, Laurie C.
    Xia, Donghui
    Qiu, Xiayang
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (05) : 413 - 419
  • [46] Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
    Tandirerung, Fistra Janrio
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 39 (2) : 405 - 413
  • [47] Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
    Tandirerung, Fistra Janrio
    CARDIOVASCULAR DRUGS AND THERAPY, 2023,
  • [48] A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia
    Brandts, Julia
    Dharmayat, Kanika, I
    Vallejo-Vaz, Antonio J.
    Sharabiani, Mansour Taghavi Azar
    Jones, Rebecca
    Kastelein, John J. P.
    Raal, Frederick J.
    Ray, Kausik K.
    ATHEROSCLEROSIS, 2021, 325 : 46 - 56
  • [49] The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
    Meshkov, Alexey
    Ershova, Alexandra
    Kiseleva, Anna
    Zotova, Evgenia
    Sotnikova, Evgeniia
    Petukhova, Anna
    Zharikova, Anastasia
    Malyshev, Pavel
    Rozhkova, Tatyana
    Blokhina, Anastasia
    Limonova, Alena
    Ramensky, Vasily
    Divashuk, Mikhail
    Khasanova, Zukhra
    Bukaeva, Anna
    Kurilova, Olga
    Skirko, Olga
    Pokrovskaya, Maria
    Mikova, Valeriya
    Snigir, Ekaterina
    Akinshina, Alexsandra
    Mitrofanov, Sergey
    Kashtanova, Daria
    Makarov, Valentin
    Kukharchuk, Valeriy
    Boytsov, Sergey
    Yudin, Sergey
    Drapkina, Oxana
    GENES, 2021, 12 (01) : 1 - 17
  • [50] Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
    Doi, Takahito
    Hori, Mika
    Harada-Shiba, Mariko
    Kataoka, Yu
    Onozuka, Daisuke
    Nishimura, Kunihiro
    Nishikawa, Ryo
    Tsuda, Kosuke
    Ogura, Masatsune
    Son, Cheol
    Miyamoto, Yoshihiro
    Noguchi, Teruo
    Shimokawa, Hiroaki
    Yasuda, Satoshi
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (04): : 1 - 11
12345